Sunitinib is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK)
inhibitor that was approved by the FDA for the treatment of renal cell ...
SUTENT® (sunitinib malate) for treatment of advanced renal cell carcinoma,
gastrointestinal stromal tumors & advanced pancreatic NET. Risk info for
Aug 15, 2016 ... Sunitinib: learn about side effects, dosage, special precautions, and more on
Oct 5, 2006 ... This page contains brief information about sunitinib malate and a collection of
links to more information about the use of this drug, research ...
Easy to read patient leaflet for sunitinib. Includes indications, proper use, special
instructions, precautions, and possible side effects.
Find out more about sunitinib (also called Sutent®), which may be used to treat a
type of kidney cancer called renal cell carcinoma (RCC), gastrointestinal ...
Learn about Sutent (Sunitinib Malate) may treat, uses, dosage, side effects, drug
interactions, warnings, patient labeling, reviews, and related medications.
Jan 13, 2016 ... Sunitinib (Sutent®) is an oral multikinase inhibitor used in the treatment of some
types of gastrointestinal stromal tumors, renal cell cancers and ...
Since sunitinib malate has shown activity in two uncontrolled studies in patients
with metastatic renal-cell carcinoma, a comparison of the drug with interferon ...
Sunitinib is an oral oxindole multitargeted kinase inhibitor that inhibits certain
receptor tyrosine kinases (RTKs). These include vascular endothelial growth